{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:34:51Z","timestamp":1770824091622,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1053\/j.seminoncol.2006.12.012","type":"journal-article","created":{"date-parts":[[2007,3,23]],"date-time":"2007-03-23T10:49:19Z","timestamp":1174646959000},"page":"85-97","source":"Crossref","is-referenced-by-count":26,"title":["Advances in the Management of Superficial Bladder Cancer"],"prefix":"10.1053","volume":"34","author":[{"given":"Michael A.","family":"O\u2019Donnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2006.12.012_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2165\/00019053-200321180-00003","article-title":"The health economics of bladder cancer: A comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.12.012_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: Epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJM200006083422301","article-title":"Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)","volume":"342","author":"Nortier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/B:CACO.0000036452.55199.a3","article-title":"Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire","volume":"15","author":"Karagas","year":"2004","journal-title":"Cancer Causes Control"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00001648-200105000-00013","article-title":"Municipal drinking water nitrate level and cancer risk in older women: The Iowa Women\u2019s Health Study","volume":"12","author":"Weyer","year":"2001","journal-title":"Epidemiology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.10191","article-title":"Familial aggregation of urothelial cell carcinoma","volume":"98","author":"Aben","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1158\/1055-9965.EPI-05-0714","article-title":"No evidence for large-scale germline genomic aberrations in hereditary bladder cancer patients with high-resolution array-based comparative genomic hybridization","volume":"15","author":"Kiemeney","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(05)67137-1","article-title":"NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses","volume":"366","author":"Garcia-Closas","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0022-5347(17)43165-X","article-title":"Transitional cell carcinoma in the Muir-Torre syndrome","volume":"138","author":"Grignon","year":"1987","journal-title":"J Urol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib13","first-page":"283A","article-title":"Contemporary profile of superficial bladder cancer revealed from an open-entry national multicenter study","volume":"171","author":"O\u2019Donnell","year":"2004","journal-title":"J Urol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/00365590050509878","article-title":"Prevention and treatment of urothelial premalignant and malignant lesions","volume":"205","author":"Wijkstrom","year":"2000","journal-title":"Scand J Urol Nephrol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000087792","article-title":"Non-invasive diagnostic tests for bladder cancer: A review of the literature","volume":"75","author":"Bassi","year":"2005","journal-title":"Urol Int"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11864-004-0028-0","article-title":"Alternatives to cytology in the management of non-muscle invasive bladder cancer","volume":"5","author":"Amiel","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib17","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of bladder cancer using a point-of-care proteomic assay","volume":"293","author":"Grossman","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","article-title":"Surveillance for recurrent bladder cancer using a point-of-care proteomic assay","volume":"295","author":"Grossman","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-5347(05)65387-6","article-title":"Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence","volume":"167","author":"Boman","year":"2002","journal-title":"Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2005.03.014","article-title":"Urine markers for bladder cancer surveillance: A systematic review","volume":"47","author":"van Rhijn","year":"2005","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib21","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1097\/01.ju.0000067461.30468.6d","article-title":"Tumor markers in the diagnosis of primary bladder cancer","volume":"169","author":"Glas","year":"2003","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","article-title":"Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analysis","volume":"61","author":"Lotan","year":"2003","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jama.285.3.324","article-title":"Urine detection of survivin and diagnosis of bladder cancer","volume":"285","author":"Smith","year":"2001","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib24","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.294.16.2052","article-title":"Relevance of urine telomerase in the diagnosis of bladder cancer","volume":"294","author":"Sanchini","year":"2005","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib25","first-page":"242","article-title":"Qualitative and quantitative histopathology in transitional cell carcinomas of the urinary bladder","volume":"70","author":"Sorensen","year":"1994","journal-title":"Lab Invest"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0094-0143(21)00411-0","article-title":"Natural history of superficial bladder cancer: Prognostic features and long-term disease course","volume":"19","author":"Heney","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/0959-8049(95)00287-S","article-title":"Factors affecting recurrence and progression in superficial bladder cancer","volume":"31A","author":"Kurth","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib28","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib29","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/S0022-5347(01)67321-X","article-title":"The relationship among multiple recurrences, progression and prognosis in patients with stage Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years","volume":"153","author":"Holmang","year":"1995","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0022-5347(17)45923-4","article-title":"Superficial bladder tumors: The importance of recurrence pattern following initial resection","volume":"135","author":"Fitzpatrick","year":"1986","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib31","first-page":"1461","article-title":"Molecular markers for diagnosis, staging, and prognosis of bladder cancer","volume":"15","author":"Williams","year":"2001","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0022-5347(05)66532-9","article-title":"Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?","volume":"165","author":"Brauers","year":"2001","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.eururo.2003.12.016","article-title":"A second-look TUR in T1 transitional cell carcinoma: Why?","volume":"45","author":"Jakse","year":"2004","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib34","first-page":"32","article-title":"[Staging error in bladder carcinoma: Anatomo-clinical correlation]","volume":"19","author":"Sanchez-Chapado","year":"1995","journal-title":"Actas Urol Esp"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib35","first-page":"915A","article-title":"The case for early cystectomy in non-muscle invasive micropapillary transitional cell carcinoma of the bladder","volume":"173","author":"Kamat","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.ju.0000132413.85866.fc","article-title":"Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: A retrospective review of the M.D. Anderson cancer experience","volume":"172","author":"Siefker-Radtke","year":"2004","journal-title":"J Urol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib37","first-page":"911A","article-title":"Lymphovascular invasion is an independent predictor of survival in cT1 bladder cancer","volume":"173","author":"Lee","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib38","first-page":"39","article-title":"Intravesical therapy: Does it affect the natural history of superficial bladder cancer?","volume":"10","author":"Lamm","year":"1992","journal-title":"Semin Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib39","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/01.ju.0000169257.19841.2a","article-title":"Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study","volume":"174","author":"Jocham","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0022-5347(05)66442-7","article-title":"Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer","volume":"165","author":"Riedl","year":"2001","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1464-410X.2004.05715.x","article-title":"5-Aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta\/T1 bladder cancer","volume":"96","author":"Babjuk","year":"2005","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0090-4295(98)00430-0","article-title":"5-Aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors","volume":"53","author":"Filbeck","year":"1999","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canlet.2005.10.036","article-title":"Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer","volume":"242","author":"Trkova","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-4295(83)90013-4","article-title":"Urothelial susceptibility to tumor cell implantation: Comparison of cauterization with N-methyl-N-nitrosourea","volume":"21","author":"Soloway","year":"1983","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib46","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1818::AID-CNCR25>3.3.CO;2-S","article-title":"Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function","volume":"86","author":"Hinotsu","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib47","first-page":"428","article-title":"p53 mutations in multiple urothelial carcinomas: A molecular analysis of the development of multiple carcinomas","volume":"10","author":"Goto","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib48","first-page":"113","article-title":"Current status of intravesical therapy for bladder cancer","volume":"vol 8","author":"Traynelis","year":"1994"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib49","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0022-5347(01)67427-5","article-title":"Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder","volume":"153","author":"Lamm","year":"1995","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib50","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: Results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ucl.2005.01.003","article-title":"Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer","volume":"32","author":"O\u2019Donnell","year":"2005","journal-title":"Urol Clin North Am"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib52","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0022-5347(17)36577-1","article-title":"Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin","volume":"148","author":"Bouffioux","year":"1992","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib54","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib55","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: Results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib56","series-title":"Phase I trial intravesical docetaxel (Taxotere) for recurrent superficial bladder cancer","author":"McKiernan","year":"2005"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1442-2042.2001.00355.x","article-title":"Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder","volume":"8","author":"Sekine","year":"2001","journal-title":"Int J Urol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-5347(18)33076-3","article-title":"Intravesical sequential chemotherapy for patients at high risk with refractory superficial bladder cancer","volume":"174","author":"Maymi","year":"2006","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib60","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2003.01.089","article-title":"Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma","volume":"21","author":"Colombo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib62","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-5347(17)42722-4","article-title":"Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors","volume":"139","author":"Kavoussi","year":"1988","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib63","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib65","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.COC.0000026911.98171.C6","article-title":"Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation","volume":"26","author":"Huncharek","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib66","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib67","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib68","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib69","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance BCG immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib70","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib72","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib73","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: From initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib75","first-page":"335","article-title":"Complications of bacillus Calmette-Guerin immunotherapy: Review of 2,602 patients and comparison of chemotherapy complications","volume":"310","author":"Lamm","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib76","first-page":"325","article-title":"Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer","volume":"310","author":"Steg","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib77","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000475204","article-title":"Improving the efficacy of BCG immunotherapy by dose reduction","volume":"27","author":"Pagano","year":"1995","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib79","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib80","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Guerin therapy: Experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"Andius","year":"2005","journal-title":"BJU Int"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.12.012_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: A solution to side-effects?","volume":"37","author":"Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib82","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","article-title":"Superficial bladder cancer: The role of interferon-alpha","volume":"159","author":"Belldegrun","year":"1998","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib83","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1464-410X.2005.05401.x","article-title":"Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma","volume":"95","author":"Ficarra","year":"2005","journal-title":"BJU Int"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib84","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000075962","article-title":"Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation","volume":"72","author":"May","year":"2004","journal-title":"Urol Int"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib85","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0090-4295(03)00584-3","article-title":"Indications for early cystectomy","volume":"62","author":"Stein","year":"2003","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib86","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1200\/jco.2005.23.16_suppl.4505","article-title":"A randomized trial of radical radiotherapy in pT1G3 NXM0 bladder cancer (MRC BS06)","volume":"23","author":"Harland","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.12.012_bib87","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","article-title":"Primary T1G3 bladder cancer: Organ preserving approach or immediate cystectomy?","volume":"172","author":"Thalmann","year":"2004","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","article-title":"Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression","volume":"141","author":"Herr","year":"1989","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib90","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib92","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib93","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: Feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib94","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/01.ju.0000149825.83180.a4","article-title":"Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization","volume":"173","author":"Kipp","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib95","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.1996.14.10.2646","article-title":"Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome","volume":"14","author":"Lacombe","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib96","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/cncr.21354","article-title":"Age and comorbidity impact surgical therapy in older bladder carcinoma patients: A population-based study","volume":"104","author":"Prout","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib97","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstrom","year":"1999","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib98","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2004.01.019","article-title":"Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder","volume":"46","author":"van der Heijden","year":"2004","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib100","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O\u2019Donnell","year":"2001","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib101","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib102","first-page":"1623","article-title":"Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer","volume":"25","author":"Akcetin","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-5347(01)63021-0","article-title":"Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder","volume":"160","author":"Nseyo","year":"1998","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib104","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.ju.0000075054.38441.2d","article-title":"Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer","volume":"170","author":"Marti","year":"2003","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib105","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0022-5347(17)32744-1","article-title":"Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: Pattern of recurrence","volume":"152","author":"Schwalb","year":"1994","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib106","first-page":"135","article-title":"Rationalization of follow-up in patients with non-invasive bladder tumors","volume":"72","author":"Morgan","year":"1993","journal-title":"Br J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib107","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2337::AID-CNCR23>3.0.CO;2-6","article-title":"Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder","volume":"86","author":"Fleshner","year":"1999","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib108","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0022-5347(17)34863-2","article-title":"Megadose vitamins in bladder cancer: A double-blind clinical trial","volume":"151","author":"Lamm","year":"1994","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2006.12.012_bib109","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.urology.2004.04.047","article-title":"Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer","volume":"64","author":"Pruthi","year":"2004","journal-title":"Urology"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib110","first-page":"913A","article-title":"Results of a randomized chemoprevention trial with finretinide in non-muscle invasive bladder cancer","volume":"173","author":"Lerner","year":"2005","journal-title":"J Urol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.12.012_bib111","first-page":"922A","article-title":"A randomized prospective phase II trial of difluoromethylornithine (DFMO) vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer","volume":"173","author":"Messing","year":"2005","journal-title":"J Urol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406004891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406004891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T18:59:11Z","timestamp":1628708351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775406004891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0093775406004891"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2006.12.012","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}